Skip to main content

Main menu

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums

User menu

  • My alerts

Search

  • Advanced search
The College of Family Physicians of Canada
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums
  • My alerts
The College of Family Physicians of Canada

Advanced Search

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • RSS feeds
  • Follow cfp Template on Twitter
Case ReportPractice

Amlodipine-induced massive gingival hypertrophy

Murat Sucu, Murat Yuce and Vedat Davutoglu
Canadian Family Physician April 2011, 57 (4) 436-437;
Murat Sucu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: sucu@gantep.edu.tr
Murat Yuce
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vedat Davutoglu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • eLetters
  • Info & Metrics
  • PDF
Loading

Drug-induced gingival hyperplasia can be a serious concern for both patients and clinicians. Drug-induced gingival hypertrophy is a well-documented side effect of some pharmacologic agents, including, but not limited to, calcium channel blockers (CCBs), phenytoin, and cyclosporine.1–3 Amlodipine, a long-acting CCB, is a commonly used hypertension drug. Here we describe a case of amlodipine-induced massive gingival hyperplasia.

Case description

A 14-year-old boy was admitted for gingival swelling. He had received a renal transplant for focal segmental glomerulosclerosis in 2005. He also had a history of hypertension, which he had been treating with oral amlodipine (10 mg twice daily) for the past 3 years. His mother said that he had been suffering from increasing gum swelling for 2 years. There was no history of any other prescription drug use during this time. Examination of the oral cavity revealed substantial diffuse gingival hypertrophy of both the upper and lower gums. The hypertrophic gingiva were painless, and there was no sign of inflammation or ulceration. He brushed his teeth regularly and his oral hygiene was normal. The rest of the physical examination findings and laboratory test results were normal. After excluding other potential causes, we considered the diagnosis of amlodipine-induced massive gingival hypertrophy. We substituted an angiotensin receptor blocker for the amlodipine, and within 6 months the gingival hypertrophy had regressed completely.

Discussion

Amlodipine is a second-generation dihydropyridine CCB that can cause gingival hypertrophy. The prevalence of amlodipine-induced gingival hypertrophy has been shown to be between 1.7% and 3.3%.4, 5 The incidence of gingival hypertrophy with nifedipine therapy has been reported to be as high as 20%,6 and a 2002 study reported that the prevalence with the use of CCBs might be as high as 38%.7

Gingival hypertrophy is 3.3 times more common in men than in women.7 The most common form is bacterial plaque–induced gingival disease, which presents as gingivitis. Use of phenytoin, cyclosporine, and CCBs, as well as vitamin C deficiency, can also cause the condition, as can hormonal shifts during pregnancy. The reason for this adverse event is not absolutely known, but mechanisms involving inflammatory and noninflammatory pathways have been suggested.8 For example, individual sensitivity to a drug’s metabolic pathway might be a trigger.8

Figure

Substantial diffuse gingival hypertrophy involving both upper and lower gums

Figure

Normal gingiva after full regression of hypertrophy

Untreated gingival hypertrophy might lead to bleeding, infection, abscess, ulceration, cosmetic deficiency, and functional difficulty (eg, chewing, talking).7 Treatment of drug-induced gingival hypertrophy includes cessation of the drug and decreasing other risk factors with meticulous mechanical and chemical plaque control. Replacing the affecting drug with another agent is also recommended when possible. Gingivectomy (excision of excessive gingival tissue) should be reserved for severe cases that affect oral hygiene or functionality, or can be performed for cosmetic reasons.

Conclusion

Our patient’s amlodipine-induced massive gingival hyperplasia completely regressed after the amlodipine was replaced by an angiotensin receptor blocker. As amlodipine is a commonly prescribed hypertension drug in family practice, every physician should be aware of this usually overlooked but potentially harmful side effect, particularly if adverse oral symptoms arise during drug use.

Notes

EDITOR’S KEY POINTS

  • Amlodipine is commonly prescribed in family practice for hypertension. Gingival hypertrophy is an often overlooked but potentially harmful side effect of treatment with amlodipine and other calcium channel blockers.

  • The patient in the case presented had gingival hypertrophy as a result of managing his hypertension with amlodipine; the problem completely resolved when he switched to an angiotensin receptor blocker.

POINTS DE REPÈRE DU RÉDACTEUR

  • On prescrit communément de l’amlodipine en pratique familiale pour l’hypertension. L’hypertrophie gingivale est un effet secondaire d’un traitement à l’amlodipine et à d’autres inhibiteurs calciques auquel on ne pense pas souvent mais qui est potentiellement dommageable.

  • Le patient dans le cas présenté avait une hypertrophie gingivale à la suite d’une prise en charge de son hypertension au moyen de l’amlodipine; le problème a complètement disparu quand il a changé ce traitement pour prendre des bloqueurs des récepteurs de l’angiotensine.

Footnotes

  • This article has been peer reviewed.

  • Competing interests

    None declared

  • Cet article a fait l’objet d’une révision par des pairs.

  • Copyright© the College of Family Physicians of Canada

References

  1. ↵
    1. Silverstein DM,
    2. Palmer J,
    3. Baluarte HJ,
    4. Brass C,
    5. Conley SB,
    6. Polinsky MS
    . Use of calcium-channel blockers in pediatric renal transplant recipients. Pediatr Transplant 1999;3(4):288-92.
    OpenUrlPubMed
    1. Infante Cossío P,
    2. Torelló Iserte J,
    3. Espín Gálvez F,
    4. García-Perla A,
    5. Rodríguez-Armijo Sánchez L,
    6. Castillo Ferrando JR
    . Gingival hyperplasia associated with amlodipine [article in Spanish]. Ad Med Interna 1997;14(2):83-5.
    OpenUrl
  2. ↵
    1. Gurm HS,
    2. Farooq M
    . Calcium channel blockers and benign hypertension. Arch Intern Med 1999;159(9):1011.
    OpenUrlPubMed
  3. ↵
    1. Jorgensen MG
    . Prevalence of amlodipine-related gingival hyperplasia. J Periodontol 1997;68(7):676-8.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Ellis JS,
    2. Seymour RA,
    3. Steele JG,
    4. Robertson P,
    5. Butler TJ,
    6. Thomason JM
    . Prevalence of gingival overgrowth induced by calcium channel blockers: a community based study. J Periodontol 1999;70(1):63-7.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Nery EB,
    2. Edson RG,
    3. Lee KK,
    4. Pruthi VK,
    5. Watson J
    . Prevalence of nifedipine-induced gingival hyperplasia. J Periodontol 1995;66(7):572-8.
    OpenUrlPubMed
  6. ↵
    1. Prisant LM,
    2. Herman W
    . Calcium channel blocker induced gingival over-growth. J Clin Hypertens (Greenwich) 2002;4(4):310-1.
    OpenUrlPubMed
  7. ↵
    1. Tavassoli S,
    2. Yamalik N,
    3. Caglayan F,
    4. Caglayan G,
    5. Eratalay K
    . The clinical effects of nifedipine on periodontal status. J Periodontol 1998;69(2):108-2.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Canadian Family Physician: 57 (4)
Canadian Family Physician
Vol. 57, Issue 4
1 Apr 2011
  • Table of Contents
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on The College of Family Physicians of Canada.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Amlodipine-induced massive gingival hypertrophy
(Your Name) has sent you a message from The College of Family Physicians of Canada
(Your Name) thought you would like to see the The College of Family Physicians of Canada web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Amlodipine-induced massive gingival hypertrophy
Murat Sucu, Murat Yuce, Vedat Davutoglu
Canadian Family Physician Apr 2011, 57 (4) 436-437;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Respond to this article
Share
Amlodipine-induced massive gingival hypertrophy
Murat Sucu, Murat Yuce, Vedat Davutoglu
Canadian Family Physician Apr 2011, 57 (4) 436-437;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Case description
    • Discussion
    • Conclusion
    • Notes
    • Footnotes
    • References
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Amlodipine induced gingival enlargement
  • Google Scholar

More in this TOC Section

Practice

  • Managing type 2 diabetes in primary care during COVID-19
  • Effectiveness of dermoscopy in skin cancer diagnosis
  • Spontaneous pneumothorax in children
Show more Practice

Case Report

  • COVID-19 vaccine-induced thrombotic thrombocytopenia
  • Shock unresponsive to Neonatal Resuscitation Program interventions
  • Addiction in the family
Show more Case Report

Similar Articles

Navigate

  • Home
  • Current Issue
  • Archive
  • Collections - English
  • Collections - Française

For Authors

  • Authors and Reviewers
  • Submit a Manuscript
  • Permissions
  • Terms of Use

General Information

  • About CFP
  • About the CFPC
  • Advertisers
  • Careers & Locums
  • Editorial Advisory Board
  • Subscribers

Journal Services

  • Email Alerts
  • Twitter
  • RSS Feeds

Copyright © 2022 by The College of Family Physicians of Canada

Powered by HighWire